Table 2

Relationship analysis between positive rate of XIAP/Smac and clinicopathologic variables

n*

XIAP-C

Smac

XIAP-N




PR

P value

PR

P value

PR

P value


Age

<50

49

42(85.7%)

20(40.8%)

21(42.9%)

≥50

53

0.789

0.145

1.000

Size

44(83.0%)

14(26.4%)

23(43.4%)

≤5 cm

77

67(87.0%)

26(33.8%)

33(42.9%)

>5 cm

25

19(76.0%)

0.212

8(32.0%)

1.000

11(44.0%)

1.000

LN status

N0

39

33(84.6%)

14(35.9%)

14(35.9%)

N1-3

63

53(84.1%)

1.000

20(31.7%)

0.672

30(47.6%)

0.305

Grade

I

25

22(88.0%)

10(40.0%)

13(52.0%)

II-III

77

64(83.1%)

0.755

24(31.2%)

0.468

31(40.3%)

0.356

ER

positive

39

31(79.5%)

14(35.9%)

20(51.3%)

negative

63

55(87.3%)

0.401

20(31.7%)

0.672

24(38.1%)

0.221

PR

positive

44

36(81.8%)

18(40.9%)

23(52.3%)

negative

58

50(86.2%)

0.591

16(27.6%)

0.204

21(36.2%)

0.112

HER2

positive

94

78(83.0%)

34(36.2%)

41(43.6%)

negative

8

8(100.0%)

0.351

0(0.0%)

0.049

3(37.5%)

1.000

XIAP-N

positive

44

41(93.2%)

16(36.4%)

/

negative

58

44(75.9%)

0.030

18(31.0%)

0.672

/


n*: number of cases. PR: positive rate. LN: lymph node. XIAP-C and XIAP-N denoted cytoplasmic immune staining score and nuclear labeling of XIAP, respectively. P-values (two sided) < 0.05 were highlighted in bold.

Zhang et al. Diagnostic Pathology 2011 6:49   doi:10.1186/1746-1596-6-49

Open Data